Breast Recurrence Score Test Market Growth - Global Industry Trend Analysis 2013 to 2017 and Forecast 2020 - 2028


Breast Recurrence Score Test  Market
  • To Be Published : Jan-2021 |
  • Status : Work in progress |
  • Format : Breast Recurrence Score Test  Market Breast Recurrence Score Test  Market Breast Recurrence Score Test  Market Breast Recurrence Score Test  Market

Breast cancer is the occurrence of cancer in cells of breast and is most common in women. Breast cancer is the second leading cause of death in women after lung cancer. Breast recurrence score test is a type of genome test to check the activity of certain genes related to breast cancer.  Breast recurrence score test is useful to decide the course of treatment for breast cancer. Breast recurrence score test also gives information on the impact and progress of chemotherapy on the patient. Breast recurrence score test can estimate the risk of breast cancer at the early stage and act accordingly. This breast recurrence score test is performed on small tissue of breast cancer extracted during the surgery. According to the American Cancer Society (ACS), 3.1 million women are currently suffering from breast cancer in the U.S.

Breast recurrence score test market is likely to have a temporary negative impact due to the pandemic with decreasing patient visits. Leading medical device manufacturers are focusing on the production of COVID-19 test kits and ventilators. Since breast cancer score test market deals with breast cancer which can be fatal, the pandemic is unlikely to have a major impact on the market.

The rise in the prevalence of breast cancer is expected to increase demand for breast recurrence score test market. High efficiency and timely results boost breast recurrence score test market growth. Prognostic nature of test increases the demand for breast recurrence score test market. Increasing awareness and investment towards breast cancer will lead to breast recurrence score test market growth. Ease of reimbursement policies will propel breast recurrence score test market growth. For instance, in October 2020 government of Germany declared government-funded health insurance will be covering the biomarker tests for breast cancer. An increasing number of diagnostic laboratories is expected to increase demand for breast recurrence score test market in the coming decade. Less healthcare expenditure in regions like the Middle East and Africa challenges the growth of breast recurrence score test market.

The global breast recurrence score test market is classified based on product type, indication, end-users and region.

Based on product type, the breast recurrence score test market is segmented into the following:

  • First-generation test
  • Second generation test

Based on the indication, the breast recurrence score test market is segmented into the following:

  • Stage I invasive breast cancer
  • Stage II invasive breast cancer
  • Estrogen receptor-positive cancer
  • Lymph node-negative breast cancer

Based on the end-users, the breast recurrence score test market is segmented into the following:

  • Hospitals
  • Speciality Cancer Centers
  • Advanced Diagnostic Centers
  • Others

The first-generation type of breast recurrence score test has a major contribution towards breast recurrence score test market. Whereas, with increasing awareness and technology second-generation product type will also have a significant contribution towards breast recurrence score test market. The major application of breast recurrence score test is invasive breast cancer with increasing prevalence towards breast recurrence score test market. Hospitals is the largest end-user of breast recurrence score test market with a large patient population. On the other hand, with the rise in the number of diagnostic laboratories advanced diagnostic centres will have significant growth rate in breast recurrence score test market during the forecast period.

Increasing prevalence of breast cancer will lead to North America dominating breast recurrence score test market during the forecast period. Ease in reimbursement policies increases the rate of breast cancer diagnostics resulting in significant growth rate for breast recurrence score test market in Europe. Whereas, the large pool of patient and government initiatives to create awareness about breast cancer are key insights responsible for the significant growth of breast recurrence score test market in the Asia-Pacific region during the forecast period. The Middle East and Africa have less advanced technology and diagnostic rate as compared to other regions, hence slower growth is estimated for breast recurrence score test market in this region.

Some key players contributing breast recurrence score test market are Roche Diagnostics, Braster, Bremed, Forward Science Technologies, Guided Therapeutics, Varian Medical Systems, LED Dental, PWB Health, Zilico Medical Diagnostics and Others.

The report on breast recurrence score test market covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Historical Actual Market Size, 2015 - 2019
  • Market Size & Forecast 2020 to 2030
  • Supply & Demand Value Chain
  • Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain
  • Market Drivers and Restraints

Regional analysis for breast recurrence score test market includes

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

 Report on breast recurrence score test market highlights:

  • Shifting industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size
  • Recent industry trends
  • Key competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Breast Recurrence Score Test Market

Back To Top